P2RY2 and hepatocellular carcinoma: Another significant finding of this study is that there is a higher frequency of P2 purinergic receptor upregulation in HCC tumors of HCV patients, as compared to those tumors with non-viral etiologies, identifying a specific subgroup of HCC with higher prevalence of P2 purinergic receptor overexpression.